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Despite a large number of different vehicles available nowadays, conventional 
emulsion systems remain one of the most commonly used for cosmetic and dermatological 
preparations. Popularly labelled as skin- and environmentally-friendly, alkyl polyglucoside 
(APG) sugar-based emulsifiers have attracted considerable interest with regard to their 
dermatological properties, since irritation potential of commonly used emulsifiers could 
affect the functionality and safety of dermopharmaceutics. The aim of this study was to 
promote the emulsion based on C16/18 APG as a prospective vehicle for topical drugs and 
cosmetic actives assessing the safety for use and skin hydration capacity. In accordance 
with the requirements of newer legislation in vitro, acute skin irritation test was performed 
using cytotoxicity assay on artificial skin. The results were compared with in vivo data 
obtained by measuring the skin biophysical parameters, such as: stratum corneum 
hydration (SCH), erythema index (EI), and transepidermal water loss (TEWL). Parameters 
were measured prior to (baseline values) and upon cessation of a 24-h occlusive treatment 
in 14 healthy human volunteers. In vivo moisturizing capacity of the emulsions was 
assessed in 16 healthy volunteers in a long-term trial measuring of SCH.  
This study showed, investigating the most frequently used APG, that emulsions 
based on these emulsifiers could probably be promoted as safe cosmetic/ 
dermopharmaceutical vehicles. Prospective safety for human use with the correlation 
between in vivo and in vitro findings was shown. In addition, the investigated vehicle per 
se showed an excellent skin moisturizing capacity which is essential in maintaining healthy 
skin, but also in improving dermatitis, which follows most pathological skin conditions. Acta 
Medica Medianae 2014;54(1): 34-39.  
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Introduction 
Creams are a common type of delivery 
systems in cosmetic and dermatological prepa-
rations, although a large number of different 
vehicles are available nowadays (1). Particularly, 
emulsions stabilized by lamellar liquid crystals 
(LLC) are intensively investigated as carriers for 
various dermopharmaceutics/dermocosmetics, 
considering their extensive similarity to the 
systems found in a living organism (e.g. stratum 
corneum (SC) lipid matrix), significant solubili-
sation capacity for lipophilic and hydrophilic 
substances and particularly the potential for 
sustained skin hydration (2,3). A formulation of 
emulsions presents a real challenge, since the 
whole series of general demands must be fulfilled: 
physicochemical stability, chemical inertness, ef-
ficacious delivery of the active, satisfactory 
aesthetic characteristics (a pleasing appearance 
which is retained during storage), optimal sensory 
attributes, pleasant skin feeling during application, 
the optimal skin hydration potential (4,5). 
Alongside the listed quality standards and expec-
tations of demandable consumers, those emul-
sions must, in the first place, have a satis-factory 
safety profile. 
If emulsion vehicles are used as drug 
carriers, they are then considered to be medicinal 
products, and they are covered by special docu-
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mentation and registration requirements (6). 
Pharmaceutical emulsion-type topical products 
must fulfil the demands for the satisfactory safety 
profile. On the other hand, cosmetic emulsions 
must meet the safety requirements of the 
Regulation (EC) 1223/2009 on cosmetics.  
Among all the pharmaceutical and cosmetic 
excipients used for emulsions, emulsifiers are 
most often recognized as potential skin irritants 
(7,8). The first step and a key feature in the 
irritation process is the interaction of the 
surfactant with the stratum corneum (SC) lipids. 
The interaction leads to the damage of the skin 
barrier, it reflects in the increased transepidermal 
water loss (TEWL) and is often followed by an 
inflammatory response. The application of emul-
sions stabilized with anionic emulsifiers is ac-
companied by adverse skin reactions (9), so, 
today, they are considered obsolete. Non-ionic 
surfactants, particularly polyethylene glycol (PEG)-
based ones (e.g. etoxylated fatty alcohols and 
fatty amphiphiles), represented for a long time the 
emulsifiers of choice, as those with the least 
potential for irritancy (10) and with the ability to 
form lyotropic liquid crystals in the presence of 
water as well. However, the PEG-emulsifiers’ 
potential to induce the barrier impairment and 
sporadic erythema on exposed healthy skin was 
indicated (9), which could be a limiting application 
factor. Some commonly used emulsifiers also have 
the ability to induce phospholipid emulsification 
contributing to cellular damage, which can result 
in cytolytic process and the release of proteins, 
lysosomal and cytoplasmic enzymes and inflam-
matory mediators (11-13). PEG-free sugar-based 
surfactants – Alkyl Polyglucosides (APGs) gain 
increasing attention due to advantages with 
regard to their biodegradability and health of 
consumers (14). 
This study investigated one of the most 
frequently used APG mixed emulsifier – Sepineo 
SETM68 INCI/ Cetearyl Glucoside & Cetearyl 
alcohol (Seppic, France). There is insufficient data 
about its performances and skin safety aspects 
assessed by manufacturer. The aim of this study 
was to formulate multicomponent emulsion based 
on this emulsifier, and to assess its skin irritation 
profile and skin moisturizing capacity. Safety 
profile was evaluated in vitro using an alternative 
method for acute skin irritation test (a cytotoxicity 
assay) (15), and in vivo on healthy human 
volunteers in a 24h-study under occlusion using the 
measure-ments of the following parameters: SC 
hydration (SCH), transepidermal water loss 
(TEWL), and skin erythema index (EI) (9). In 
addition, we checked the in vivo moisturizing ef-
ficacy of this emulsion sample in short-term (3 
hours) study measuring SCH. 
Material and methods 
A multiphase oil/water (o/w) cream based 
on Sepineo SETM68 (kindly provided by Seppic, 
France) sugar emulsifier in the concentration of 
7% (w/w) was formulated and marked as M68. 
The sample was adequately preserved using Euxyl 
K®300 (Schülke&Mayr, Germany) preservative 
blend. The humectant used was glycerol (BASF, 
Germany) at 2% (w/w). For the purpose of the 
preparation of the sample, emulsifier and 16% 
(w/w) oil phase which consisted of: isopropyl-
miristate (Unichemcom, Austria), caprylic-capric 
triglycerides (МyritolTM 318, Henkel, Germany), 
decyl oleate (SabodermTM DO, SABO, Italy), 
mineral oil (BASF, Germany), cetearyl alcohol 
(Lanette 0, Cognis, Germany) and dimethicone 
(Abil®100, Cognis, Germany) were heated at 70°C, 
and then added to the preserved water phase at 
the same temperature by stirring (stirrer RW16 
basic, IKA®WERKE, Germany) at constant tempe-
rature for 5min (800rpm). Cooling was started 
while mixing at 500rpm 3min, then at 300rpm to 
the room temperature.  
For the cell culture experiments, human 
dermal fibroblasts from the foreskin of newborns 
were used. These cells were obtained from Cascade 
Biologics (Mansfield, UK), cultured according to 
standard conditions and used from the third to the 
twelfth passage. Immortalised keratinocytes from 
the HaCaT-cell line (Human adult, low Calcium, 
elevated Temperature) were used according to a 
standard cell culture method during passages 68–
84 (16). For cytotoxicity (MTT) experiments, 3-
(4,5)-dimethylthiazol-2-yl)-2.5-diphenyl tetra-
zolium bromide (Sigma, Steinheim, Germany), 
sodium dodecylsulphate (Acros, B-Geel), isopropa-
nol (RiedeldeHaën, Seelze, Germany), hydro-
chloric acid (Merck, Darmstadt, Germany) and 
freshly double distilled water were used. Artificial 
skin construct (ASC) was manu-factured and a 
modified version of Mosman´s method (17) was 
used for the in vitro acute skin irritation test-a 
cytotoxicity assay as previously described (3). 
Additionally, an in vivo bioengineering study 
was also performed. Skin parameters TEWL, EI, 
SCH were measured prior to (baseline values) and 
60min upon cessation of 24h occlusive treat-ment. 
Fourteen healthy female volunteers (27.4±1.1 
years) were recruited. The flexor side of their left 
forearms was treated with investigated emulsion 
using precisely delineated and marked cardboard 
ruler (with empty spaces in the form of rectangles, 
16cm2 each). Two additional sites were left as a 
non-treated control under occlusion (UCO) on the 
right forearm and without occlusion (UC) on the 
left. Sample was applied in quantity of 0.016g/cm2, 
spread vigorously with rubber glove, and im-
mediately covered with Parafilm® and than with 
cotton adhesive tapes. All parameters were 
measured according to the published guidelines 
and documents (18). 
To estimate the moisturizing efficacy of the 
same sample in vivo by measuring EC, additional 
group of 16 healthy volunteers (24.2±1.6 years) 
was recruited. They all took part in short- (3h) 
term trial. The flexor side of their left forearm was 
treated with the emulsion sample using cardboard 
ruler as described. One rectangle was left as an 
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untreated control (UC) on the right forearm. The 
amount of applied sample was 0.016g/cm2, and 
the measurements conducted were: baseline, 1,2, 
and 3 hours after application. 
In vivo measurements were performed in 
accordance with the Declaration of Helsinki, and 
the volunteers signed a written consent. They 
were informed of the study and instructed not to 
use any skin cleansing or skin care product on the 
test sites for the whole week before the study, and 
during the experiment. The study was approved 
by the local Ethical Committee on Human 
Research. All subjects had healthy skin and no 
known allergy to any ingredient of the sample. 
Before any measurements were taken, the 
subjects were asked to acclimatize for 30min 
under controlled conditions (21±1°C and 50±5% 
RH). TEWL was measured using Tewameter®TM 
210, EI using Mexameter®MX 18, and SCH by 
means of Corneometer®CM 825 (all Courage + 
Khazaka, Germany). 
All data were presented as means +/- 
standard error of the means (SEM). In vivo 
measured parameters (SCH, TEWL, EI) were 
expressed as absolute changes to baseline (Δ 
values) values, second versus first day for irritation 
testing. The values obtained for M68 to UCO and 
UC were compared using one-way ANOVA, followed 
by Tukey’s t-test, where appropriate. For moistu-
rizing efficacy testing SCH was presented as 
percent change compared to baseline for M68 and 
UC. SCH for the sample in distinct time points was 
compared using a paired sample t-test. 
The differences were accepted as statis-
tically significant at p<0.05. Statistical analysis 
was performed with commercial statistical software 
SPSS for Windows 13.0. 
Results 
The sample was applied to the ASCs in 
three different concentrations: 0.25%, 2.5% and 
25%. The results for the in vitro skin irritation test 
are presented in Figure 1.  
The results for in vivo investigation of skin 
irritation potential are shown in Figures 2a, 2b. 
Parameters were shown as ΔTEWL, ΔSCH and ΔEI 
- absolute changes of mean values for treated  
sites and untreated controls, after 24h occlusion 
related to the baseline values. All participants 
reported strict compliance with the initially given 
instructions. 
Figure 1. In vitro skin irritation test, concentration-
viability histograms for the sample M68 
The results of the moisturizing efficacy of 
the sample M68 are presented in Figure 3. The 
application resulted in a significant improvement 
of skin moisture (increase of SCH), compared to 
both UC and baseline in a short-term study. 
Figure 3. The effect of topical application of the sample 
M68 related to baseline (percent change) in a short-
term study (SCH measurements). Significant 
differences (P<0.05) are marked with (*) 
a b 
Figure 2. In vivo skin irritation test - the influence of the sample M68 on parameters a) SCH, EI and b)TEWL and both controls 
(under occlusion UCO and without occlusion UC); the results are shown as absolute changes of mean values on the second vs. first 
day and standard error of means. Significant differences (P<0.05) are marked with (*) for denoting the differences between the 
baseline and obtained values, and also to mark the mutual differences.
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Dermal irritation is defined as the produc-
tion of "reversible damage of the skin following the 
application of a test substance for up to 4 hours". 
It was generally assessed by the potential of a 
certain substance/product to cause erythema 
/eschar and/or oedema after a single topical 
application on rabbit skin and based on the Draize 
score (19). In fact, skin irritation profile of topicals 
and raw materials was, alongside other aspects of 
toxicity, assessed routinely and reliably using in 
vivo animal testing until recently. Ethical concerns 
involving the use of laboratory animals, the validity 
of animal skin as human skin models, and the need 
for more efficient validation methods have 
promoted the development of alternative methods 
to assess irritation (15). Moreover, the sales ban 
on animal-tested cosmetics prohibits the sale on 
the EU market of any cosmetic product that has 
been tested on animals or using alternative 
methods other than those validated by the 
European Centre for Validation of Alternative 
methods (ECVAM) or the Organisation for Euro-
pean Economic Co-operation and Development 
(OECD) (20). Nowadays, there are alterna-tive 
ways to perform irritancy tests. The artificial skin 
constructs are being used, employing alterna-tive 
method for acute skin irritation test (cytotoxicity 
assay) validated by ECVAM (21). In order to 
compare the value of this in vitro test with the 
actual outcome, parallel in vivo tests on humans 
should normally be employed (22). 
In accordance with the requirements of 
current legislation, the determination of skin 
irritation potential of APG based emulsion was 
performed in our study using both described in 
vivo and in vitro methods, which is compulsory in 
order to draw a definitive conclusion on irritation 
potential of the product. In this study, an in–house 
three dimensional human skin model, involving 
the reconstructed epidermis with functional stratum 
corneum, was used for in vitro study. More 
precisely, quantitative cell viability was determi-
ned as a percentage of negative control and is 
used to predict the irritation potential – if the 
mean cell viability is less than or equal to 50%, a 
product can be defined as a local irritant; other-
wise, its skin irritation profile could be chara-
cterized as favourable (19) which was shown for 
our sample (Fig. 1).  
Regarding in vivo measurements of the 
skin, there is not a single biophysical parameter 
efficient to embrace fully all pathophysiologic 
aspects of skin irritancy. A multi-parametric ap-
proach in the assessment of the skin irritation 
potential of topical emulsions is proposed when 
employing biophysical measurements (14). The 
effects of irritants have previously been studied by 
measurements of transepidermal water loss (TEWL) 
and skin color (23). Since the increase in TEWL is 
observed after the application of skin irritants, 
Discussion TEWL measurements are often used in support of 
cosmetic claims of product mildness (18). Erythema 
index (EI) measured by Mexameter® was shown to 
be an adequate parameter for objective evalu-
ation of skin irritation (24).  
Investigated APG- based emulsion have 
shown increased EI value after application, but no 
statistically significant change was found (Fig. 2a). 
This could support the claim that the investigated 
emulsion is not expected to cause immediate 
irritation of the skin. At the same time, the 
emulsion efficiently hydrated the skin which is 
shown as the SCH increase after 24h (Fig 2a).  
Barrier function of the skin is dependent on 
the intercellular lipid phase of SC; it has been 
shown that changes in the lipid content and 
organization of the intercellular lipids influence the 
performance of the barrier (23). After the 
application of the APG-based emulsion, the 
decrease of TEWL was noticed (Fig. 2b), and it 
could be interpreted as a repair of the barrier 
function. This could probably be attributed to the 
specific, skin-friendly colloidal structure of those 
emulsion systems. It was shown that APG-based 
vehicles mimic SC organization well, as the result 
of lyotropic liquid crystals formation (3,15). 
Similarity between the emulsions’ liquid crystalline 
structure and the structure of physiological skin 
lipids, rather than a simple deposition of lipid 
material to the surface, is probably responsible for 
the decrease in TEWL, that is, for a "streng-
thening" of the SC barrier. It is possible that this 
beneficial effect is also the result of the increased 
skin hydration, which consequently improves SC 
elasticity. 
In vivo/in vitro investigations in this study 
showed the absence of skin irritation, pointing to 
the satisfying skin safety profile of this emulsifier 
and additional APG-based emulsions benefits to 
the skin.  
Topical moisturizers are essential in 
enabling the skin to stay intact as well as in the 
topical treatment of some diseases such are psori-
asis, ichtyosis, atopic dermatitis (18). Thus, it 
could be of great benefit for emulsion vehicle to 
show good skin moisturizing potential and to 
hydrate the skin even a few hours after its topical 
application. Regarding our investigation, three 
hours after the application of the sample M68, 
significantly higher SCH compared to baseline was 
measured, indicating significant potential of the 
sample M68 for prolonged skin hydration (Fig. 3). 
Conclusion 
Overall, this study showed that C 16/18 
APG-based vehicles could be promoted as safe for 
cosmetic/dermopharmaceutical use. So far, there 
has been a considerable body of evidence to 
support the claim that APG emulsifiers, particularly 
in the form of emulsifying waxes, could be used in 
the formulation of advanced, sophisticated phar-
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maceutical and cosmetic emulsion-type topical 
products. Comparison of the results from in vivo 
skin irritation potential assessment for APG-based 
emulsions with complementary in vitro cytotoxicity 
assay from this study reveals a correlation 
between the two confirming that topical emulsions 
based on the most commonly used APG mixed 
emulsifier are not expected to cause irritation of 
the skin, when used in concentrations correspon-
ding to the therapeutic need, i.e. to the need of 
the cosmetic treatment. Besides being mild to the 
skin, the investigated agent plays an ameliorative 
role in improving the overall health of the skin 
barrier. Its use could be even taken into conside-
ration when formulating emulsion vehicles for 
cosmetic actives and drugs with unfavourable 
safety profile. 
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NOVIJI PRIRODNI ŠEĆERNI EMULGATORI NAMENJENI IZRADI 
NOSAČA ZA DERMATOLOŠKE LEKOVE I KOZMETIČKI AKTIVNE 
SUPSTANCE – ISPITIVANJE BEZBEDNOSTI I EFIKASNOSTI 
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Emulzije su najčešće korišćeni nosači u izradi kozmetičkih proizvoda i 
dermatoloških lekova. Emulgatori, obavezni sastojci emulzija, mogu da poseduju visok 
potencijal da iritiraju kožu i oštećuju njenu barijeru. Nasuprot konvencionalnim, alkil 
poliglukozidi (APG) kao noviji, blagi, biodegradabilni emulgatori, danas privlače veliku 
pažnju. Smatra se da, osim što ne iritiraju, pokazuju dodatne pozitivne efekte pri lokalnoj 
aplikaciji kao što je vlaženje kože. Cilj studije bio je ispitivanje emulzija stabilisanih 
jednim od najčešće korišćenih C16/18 APG, i to u smislu bezbednosti za upotrebu i 
potencijala za hidrataciju kože. U skladu sa najnovijom zakonskom regulativom u ovoj 
oblasti, potencijal za lokalnu iritaciju određen je in vitro testom citotoksičnosti na 
veštačkoj koži, kao i in vivo merenjem biofizičkih parametara kože na humanim 
dobrovoljcima: električna kapacitivnost (SCH), eritema indeks (EI) i transepidermalni 
gubitak vode (TEWL). Merene su bazalne i vrednosti parametara 24h nakon aplikacije 
uzorka okluzijom. Kapacitet uzorka da efikasno i produženo hidratiše kožu određivan je in 
vivo merenjem parametra SCH nakon jednokratne aplikacije.  
Ispitujući emulzije stabilisane jednim od najčešće korišćenih APG, studija je 
pokazala da se ovi emulgatori verovatno mogu smatrati bezbednim u izradi kozmetič-
kih/dermofarmaceutskih nosača, pri čemu su rezultati in vivo i in vitro ispitivanja bili su u 
međusobnom skladu. Nije registrovan iritacioni potencijal korišćenog APG, inače čest 
problem pri upotrebi konvecionalnih emulgatora starijih generacija, a pokazan je odličan 
potencijal emulzija sa C16/18 APG za efikasnu i prolongiranu hidrataciju. Poslednje može 
biti od velikog značaja u tretmanu zdrave, ali naročito kože zahvaćene dermatitisom koji 
je pratilac većine patoloških stanja kože. Acta Medica Medianae 2015;54(1):34-39. 
Ključne reči: emulgatori, alkil poliglukozidi, dermatološki lekovi, kozmetički 
proizvodi, in vivo/in vitro bezbednost i efikasnost na koži; biofizički parametri kože; 
hidratacija kože 
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